tiprankstipranks
Advertisement
Advertisement

BPTSY Stock Latest News

Biophytis Registers Hong Kong Joint Venture to Drive BIO101 Expansion in Asia
Company AnnouncementsBiophytis Registers Hong Kong Joint Venture to Drive BIO101 Expansion in Asia
3d ago
6K
Biophytis Files Hong Kong Joint Venture Registration to Drive BIO101 Expansion in Asia
PremiumCompany Announcements
Biophytis Files Hong Kong Joint Venture Registration to Drive BIO101 Expansion in Asia
10d ago
6K
Biophytis Converts Hexagon Bond Line Into Cheaper €2m Revolving Facility to Back Phase 3 Sarcopenia Push
PremiumCompany Announcements
Biophytis Converts Hexagon Bond Line Into Cheaper €2m Revolving Facility to Back Phase 3 Sarcopenia Push
15d ago
6K
Biophytis Delays 2025 Annual Results Following €2 Million Refinancing Focus
PremiumCompany Announcements
Biophytis Delays 2025 Annual Results Following €2 Million Refinancing Focus
1M ago
6K
Biophytis Showcases AI-Driven Longevity Drug Discovery with LynxKite at NVIDIA GTC 2026
PremiumCompany Announcements
Biophytis Showcases AI-Driven Longevity Drug Discovery with LynxKite at NVIDIA GTC 2026
3M ago
6K
Biophytis Raises €2 Million, Clears Convertible Debt to Fund Longevity Trials
PremiumCompany AnnouncementsBiophytis Raises €2 Million, Clears Convertible Debt to Fund Longevity Trials
3M ago
6K
Biophytis Doubles Hexagon Bond Facility to €2 Million and Extends Maturity
Premium
Company Announcements
Biophytis Doubles Hexagon Bond Facility to €2 Million and Extends Maturity
4M ago
6K
Biophytis Targets Muscle Loss in GLP-1 Weight Loss Users With New Phase 2 Trial
Premium
Company Announcements
Biophytis Targets Muscle Loss in GLP-1 Weight Loss Users With New Phase 2 Trial
4M ago
BPTSY
Biophytis Strikes Asia Joint Venture and Secures $20 Million to Fund Phase 3 Sarcopenia Trial
PremiumCompany Announcements
Biophytis Strikes Asia Joint Venture and Secures $20 Million to Fund Phase 3 Sarcopenia Trial
5M ago
6K
Biophytis Announces Approval of Resolutions at General Meeting
PremiumCompany Announcements
Biophytis Announces Approval of Resolutions at General Meeting
7M ago
6K
Biophytis Releases Interim Financial Report for H1 2025
PremiumCompany Announcements
Biophytis Releases Interim Financial Report for H1 2025
7M ago
6K
Biophytis Partners with Asian Consortium for Landmark Sarcopenia Trial
PremiumCompany Announcements
Biophytis Partners with Asian Consortium for Landmark Sarcopenia Trial
8M ago
6K
Biophytis Secures Brazilian Funding for Obesity Trial
PremiumCompany AnnouncementsBiophytis Secures Brazilian Funding for Obesity Trial
9M ago
6K
Biophytis Unveils Phase 3 Sarcopenia Trial Strategy in Europe and Asia
Premium
Company Announcements
Biophytis Unveils Phase 3 Sarcopenia Trial Strategy in Europe and Asia
9M ago
6K
Biophytis Secures EMA Approval for Phase 2 Obesity Trial
Premium
Company Announcements
Biophytis Secures EMA Approval for Phase 2 Obesity Trial
9M ago
6K
Biophytis Announces Phase 2 Obesity Trial Strategy for BIO101
PremiumCompany Announcements
Biophytis Announces Phase 2 Obesity Trial Strategy for BIO101
9M ago
6K
Biophytis Gains Approval for Phase 3 Sarcopenia Trial
PremiumCompany Announcements
Biophytis Gains Approval for Phase 3 Sarcopenia Trial
10M ago
6K
Biophytis Secures Legal Victory in French Court
PremiumCompany Announcements
Biophytis Secures Legal Victory in French Court
11M ago
6K
Biophytis Partners with Lynx Analytics to Boost Sarcopenia Drug Discovery
PremiumCompany Announcements
Biophytis Partners with Lynx Analytics to Boost Sarcopenia Drug Discovery
11M ago
6K
Biophytis Showcases BIO101 at World Aging Conference 2025
PremiumCompany AnnouncementsBiophytis Showcases BIO101 at World Aging Conference 2025
11M ago
6K
Biophytis Announces 2024 Financial Results and Strategic Plans for 2025
Premium
Company Announcements
Biophytis Announces 2024 Financial Results and Strategic Plans for 2025
11M ago
6K
Biophytis Showcases Innovations at BIO International 2025
Premium
Company Announcements
Biophytis Showcases Innovations at BIO International 2025
11M ago
6K

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >